<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="210">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437151</url>
  </required_header>
  <id_info>
    <org_study_id>US10022</org_study_id>
    <nct_id>NCT00437151</nct_id>
  </id_info>
  <brief_title>Analysis of Adherence &amp; Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%</brief_title>
  <official_title>An Analysis of Adherence and Associated Factors in Subjects Undergoing Differin® Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to investigate potential differences in treatment
      adherence by teenagers among four interventions during treatment for acne.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy - Percent adherence calculated from MEMS Caps readings</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy - lesion counts; percent adherence as calculated by product weights and by Subject's Diary; Global Severity Assessment; Global Assessment of Improvement; Subject questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - tolerability and adverse event reporting</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>More frequent than normal office visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electronic reminders (voice, e-mail, text messages)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Parental involvement / intervention reminders</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intervention or reminders</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>More frequent than normal office visits</intervention_name>
    <description>Mode of patient reminder</description>
    <arm_group_label>1</arm_group_label>
    <other_name>More frequent than normal office visits</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic reminders (voice, e-mail, text messages)</intervention_name>
    <description>Mode of patient reminder</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Electronic reminders (voice, e-mail, text messages)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Parenteral involvement / intervention reminders</intervention_name>
    <description>Mode of patient reminder</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Parenteral involvement / intervention reminders</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention or reminders</intervention_name>
    <description>Mode of patient reminder</description>
    <arm_group_label>4</arm_group_label>
    <other_name>No intervention or reminders</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adolescent subjects with a diagnosis of moderate to severe Acne vulgaris

        Exclusion Criteria:

          -  Subjects with acne conglobata, acne fulminans, secondary acne (chloracne,
             drug-induced acne, etc.), or severe acne requiring more than topical treatment (e.g.
             oral isotretinoin)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald W Gottschalk, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma Laboratories, LP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <lastchanged_date>March 27, 2008</lastchanged_date>
  <firstreceived_date>February 16, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Ronald W. Gottschalk, MD / Medical Director</name_title>
    <organization>Galderma Laboratories, L.P.</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
